Compare Cassava Sciences Inc (FLNA) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Vanguard Real Estate Index Fund ETF trades at $99.29. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | VNQ | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | — |
52-Week High | $4.64 | $98.66 |
52-Week Low | $1.09 | $87.00 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
VNQ (Vanguard Real Estate ETF) trades at $98.865, up 1.33% with a bullish technical signal supported by 16 buy indicators. The ETF has delivered a 12% year-to-date total return through mid-July 2026, though the rally has recently stalled. Technical analysis shows strong bullish momentum in moving averages while oscillators remain neutral. Recent news highlights VNQ's competitive expense ratio and liquidity advantages over peers, with real estate ETFs broadly outperforming the market despite interest rate pressures.
The outlook for VNQ remains positive given real estate sector momentum and AI-driven data center REIT performance, though sensitivity to Treasury yields presents near-term risk. Income investors benefit from the ETF's diversified real estate exposure without landlord responsibilities. Key risks include interest rate volatility and inflation persistence, but the sector shows resilience with REIT-rate correlations weakening as fundamentals improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
